A5025258875- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Glutathione Transferases and Polymorphisms
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Circular RNAs in diseases
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Angiogenesis and VEGF in Cancer
- RNA modifications and cancer
- Phagocytosis and Immune Regulation
- Lung Cancer Treatments and Mutations
- Cancer, Stress, Anesthesia, and Immune Response
- Cytokine Signaling Pathways and Interactions
INCLIVA Health Research Institute
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Centre for Biomedical Network Research on Rare Diseases
2021-2025
Weatherford College
2024
Biomedical Research Institute
2014-2024
Universitat de València
1995-2023
Universitat Politècnica de València
2022-2023
European Society of Anaesthesiology
2022
Hospital Clínico Universitario de Valencia
2006-2021
Instituto de Salud Carlos III
2019-2021
There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons 182 cancer-related genes plus 37 introns from 14 often rearranged Point mutations, indels, copy-number (CNA), select rearrangements were assessed 74 tumors 43 patients (36 38...
// Raúl Rincón 1, * , Ion Cristóbal Sandra Zazo 2 Oriol Arpí 4 Silvia Menéndez Rebeca Manso Ana Lluch 3 Pilar Eroles Rovira Joan Albanell Jesús García-Foncillas 1 Juan Madoz-Gúrpide Federico Rojo 2, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital "Fundación Jiménez Diaz", Madrid, Spain Pathology Department, IIS of INCLIVA, Valencia, Medical del Mar, Barcelona, These authors have contributed equally to this work Correspondence to:...
Abstract The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this could optimize treatment response. Here we analyzed the involvement miRNA-449 family response to doxorubicin. cell viability, cell-cycle phases, expression silico target genes proteins sensitive/resistant lines were evaluated doxorubicin after gain/loss miRNAs-449 function achieved by transient transfection. Triple patients selected for ex vivo...
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism trastuzumab orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation PI3K/AKT MAPK pathways ligand-independent manner. Genetic depletion pharmacological inhibition restored response vitro vivo. inhibitor plus achieved complete...
Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated pulse-fashion with induce resistant phenotype. Cellular molecular effects parental versus compared. CDK1 kinase activity cyclin B1 expression assayed under various conditions. Genetic modifications up- or...
Abstract A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, their target gene CCNE2 seems play an important role in therapy. Cell viability was evaluated treated BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate MDA-MB-231 (HER2−) cell lines, the expression miR-26a, miR-30b, genes measured. decreased by 60% were significantly overexpressed (~3-fold, p =...
Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits progression and metastasis through downregulating ZEB1 ZEB2. Based on above, we describe design validation nanodevice using mesoporous silica nanoparticles delivery...
Breast cancer is rarely diagnosed in very young women (35 years old or younger), and it often presents with distinct clinical-pathological features related to a more aggressive phenotype worse prognosis when at this early age. A pending question whether breast arises from the deregulation of different underlying mechanisms, something that will make disease an entity differentiated older patients.We performed comprehensive study miRNA expression using Affymetrix2.0 array on paraffin-embedded...
Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated role an epigenetic methylation-based signature. Epigenetic assessment DNA extracted from biopsy archived samples previous to NAC TNBC patients was performed. Patients included were categorized according responder (pCR or residual burden, RCB = 0) non-responder (non-pCR >...
Metformin, a drug approved for diabetes type II treatment, has been associated with reduction in the incidence of breast cancer and metastasis increased survival diabetic patients. High levels miR-26a expression have proposed as one possible mechanisms this effect; likewise, miRNA also survival/apoptosis processes cancer. Our aim was to evaluate if some its targets could mediate effect metformin The viability MDA-MB-231, MDA-MB-468, MCF-7 cell lines evaluated an MTT assay after ectopic...
Screening cDNA libraries with polyclonal antibody preparations against Candida albicans yeast or mycelial cell walls resulted in isolation of several positive clones. Some them encoded enolase; others a protein the 70 kDa heat-shock family (Hsp70p), etc. The presence these cytosolic proteins wall actively growing C. was discovered by analytical (SDS-PAGE and Western blot) cytological (indirect immunofluorescence) experiments. Supplementation cultures papulacandin B, an antibiotic that...
HER2-positive breast cancer is currently managed with chemotherapy in combination specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due molecular alterations the tumor that are unknown undetermined clinical practice. Those may cause be refractory treatment trastuzumab, promoting proliferation and metastasis. Using continued exposure cell line we...
MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours plasma of cancer patients to evaluate its usefulness a minimally invasive biomarker. MiR-99a-5p were determined by quantitative real-time PCR three independent cohorts patients: (I) Discovery cohort: tissues (n = 103) healthy 26); (II) Testing samples from 105 98 donors; (III) Validation 89 85 donors. Our results demonstrated that was...
Our results show the following:•Low miR-30b-5p expression was detected in breast tumor tissue compared with healthy tissue.•High circulating levels plasma were associated to cancer.•miR-30b-5p identify cancer of all subtypes and stages disease.•Circulating relate patients' burden.•Circulating is a potential non-invasive cost-effective diagnostic BC biomarker. BackgroundRecently, microRNAs have been demonstrated be biomarkers for diagnosis, prognosis assessment or prediction response...
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains main clinical challenge. In order evaluate implication microRNAs in trastuzumab response, we performed a microRNA array parental and acquired trastuzumab-resistant cell lines. Our results identified miR-146a-5p as dysregulated microRNA. Interestingly, high expression primary tumor tissue correlated with shorter disease-free survival The...